The overexpression of CGRP is an important cause of migraine (Edvinsson et al., 2018; Ho et al., 2010; Pellesi et al., 2017; Russell et al., 2014; Russo, 2015; Tepper, 2018), and several monoclonal antibodies (eptinezumab, fremanezumab, galcanezumab, and erenumab) against CGRP or CGRP receptors have been approved by the FDA as therapeutics for migraine patients. Here, CALCA is linked to migraine disorder.